Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Capital Expenditures: 2019-2025

Historic Capital Expenditures for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $171,000.

  • Allogene Therapeutics' Capital Expenditures fell 60.14% to $171,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $643,000, marking a year-over-year increase of 2.06%. This contributed to the annual value of $694,000 for FY2024, which is 54.22% down from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Capital Expenditures is $171,000, which was up 47.41% from $116,000 recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Capital Expenditures ranged from a high of $9.1 million in Q2 2021 and a low of $8,000 during Q1 2024.
  • For the 3-year period, Allogene Therapeutics' Capital Expenditures averaged around $259,600, with its median value being $176,000 (2023).
  • Over the last 5 years, Allogene Therapeutics' Capital Expenditures had its largest YoY gain of 3,475.00% in 2024, and its largest YoY loss of 99.23% in 2024.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Capital Expenditures stood at $736,000 in 2021, then soared by 129.89% to $1.7 million in 2022, then tumbled by 89.30% to $181,000 in 2023, then surged by 41.99% to $257,000 in 2024, then slumped by 60.14% to $171,000 in 2025.
  • Its last three reported values are $171,000 in Q3 2025, $116,000 for Q2 2025, and $99,000 during Q1 2025.